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Abstract 
The transcriptional programs guiding lymphocyte differentiation depend on precise expression 
and timing of transcription factors (TFs). BTB And CNC Homology 2 (BACH2) is a TF essential 
for both T and B lymphocytes that is associated with an archetypal super-enhancer (SE). Single 
nucleotide variants (SNVs) in the BACH2 locus have been associated with multiple autoimmune 
diseases but BACH2 mutations have not previously been shown to cause Mendelian monogenic 
primary immunodeficiency. Herein, we describe an autosomal dominant syndrome of BACH2-
related immunodeficiency and autoimmunity (BRIDA) in three patients from two independent 
kindreds, resulting from haploinsufficiency of BACH2. Patients had lymphocyte maturation 
defects, resulting in both immunoglobulin deficiency and intestinal inflammation. The mutations 
disrupted BACH2 protein stability by interfering with homodimerization or by causing 
aggregation. Analogous lymphocyte defects were noted in a murine Bach2 heterozygous 
deficiency model, confirming that the loss of one allele is sufficient to recapitulate key cellular 
phenotypes of the disease. More generally, we found that genes causing monogenic 
haploinsufficient diseases are substantially enriched for TFs and SE-architecture. These 
observations show a new feature of genes with SE architecture in Mendelian diseases of 
immunity and suggest that heterozygous mutations in SE-regulated genes identified on whole 
exome/genome sequencing may have greater significance than previously recognized. 
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Introduction 
The inheritance pattern of genetic diseases consists of a spectrum, ranging from the vast majority 
representing polygenic susceptibility variants (usually identified on GWAS studies) to the 
minority, which are monogenic and manifest in either a recessive or dominant manner. It is now 
appreciated that mutations in over 300 different genes can cause primary immunodeficiency 
(PID), many of which affect T and B lymphocyte function1-4. PIDs are often paradoxically 
associated with autoimmunity3-7. Common variable immunodeficiency (CVID), a major form of 
PID with antibody deficiency, is typically associated with recurrent infections and 
autoimmunity8. Recently developed gene-sequencing technologies now allow for rapid 
identification of PIDs but have also raised the important question of how to interpret the many 
heterozygous mutations seen in both patients and healthy controls. Relatively few PID syndromes 
are caused by haploinsufficiency, an autosomal dominant pattern of disease inheritance, where 
one allele is damaged and only a single functional allele remains9. Genes, such as CTLA4, are 
particularly susceptible to haploinsufficiency and the reasons are unknown10. In the light of many 
healthy people that harbor heterozygous loss of function or hypomorphic variants, why should 
partial changes in gene expression have significant consequences to health? 
 
Promoters and enhancer elements govern gene expression. Most, such as housekeeping genes like 
actin, are regulated by a limited number of associated enhancers, known as “typical enhancers”11. 
By contrast, 5-10% of genes have a complex enhancer structure consisting of multiple enhancers 
that collectively are described as SEs12,13. Genes with associated SEs have a highly regulated 
pattern of gene expression; single nucleotide polymorphisms associating in GWAS studies with 
autoimmune diseases are preferentially enriched within SE regions14. These findings suggest the 
hypothesis that minor changes in regulatory function at SE regions could have significant 
consequences to the immune system for genes regulated by SEs. 
 
BACH2 is a typical example of an SE regulated gene associated with autoimmune disease. It is a 
highly conserved member of the basic and leucine zipper domain (bZIP) superfamily of TFs and 
a critical regulator of both T and B lymphocyte differentiation and maturation15,16. 
Polymorphisms in the human gene locus associate with multiple autoimmune diseases, including 
asthma17, insulin dependent diabetes mellitus18, Crohn’s and celiac diseases19,20, vitiligo21 and 
multiple sclerosis16,22. The Bach2 gene locus has the largest SE structure seen in mouse 
lymphocytes14. Homozygous deletion of Bach2 in mice results in spontaneous fatal autoimmunity 
between 3 and 9 months of age15. Functionally, Bach2 acts as a repressive “guardian” TF that 
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regulates the balance between a network of other TFs critical to T and B cell specification and 
maturation. In B cells, Bach2 controls the balance between Pax5 and Blimp1 by repressing the 
latter23,24, to decelerate plasma cell differentiation and permit antibody class switch recombination 
(CSR) (allowing expression of IgA, G and E isotypes)25. Consequently, mice lacking Bach2 have 
B cells with impaired CSR that rapidly differentiate into IgM-restricted plasma cells. In T cells, 
Bach2 regulates networks of genes that control T cell effector lineages14 and cellular 
senescence26, thus limiting differentiation into effector cells 15 and promoting development of 
FoxP3+ regulatory T cells (Tregs). Tregs are a non-redundant suppressive lineage of T cells that 
prevent development of autoimmune diseases by controlling over-activation of the immune 
system27. Thus, mice deficient in Bach2 demonstrate both a paucity of Tregs and an excess of 
memory/effector T cells that age and die prematurely, resulting in autoimmunity.  
 
Structurally, Bach2 contains a BTB/POZ domain that mediates homo-and hetero-dimerization at 
its N-terminus and a bZIP domain at the C-terminus required for DNA binding. The dimerization 
domain is an alpha-helical structure containing a cysteine residue that is capable of forming a 
disulphide bond with its opposite partner28. Thus homo-dimerization is likely to be stabilized by a 
covalent modification that occurs soon after protein folding. Bach2 dimers translocate to the 
nucleus where they interact with target DNA loci at palindromic Maf recognition elements 
(MARE), either alone or in collaboration with other members of the bZIP family, such as the 
small Maf proteins (MafF, MafG and MafK)16. This interaction, for example at the Prdm1 locus 
that encodes Blimp1, represses gene expression.   
 
Here we describe a novel PID caused by haploinsufficiency of BACH2 and propose a shared 
genetic mechanism to explain why some genes are particularly susceptible to causing disease by 
haploinsufficiency and should be regarded as significant and prioritized in the interpretation of 
heterozygote variants found on whole exome sequencing.  
Results 
Mutations in the BACH2 gene locus are associated with CVID and colitis 
We investigated a female (Figs. 1a and 1b – Family A) with infancy-onset colitis, who became 
ill at 19 years old with non-infectious fever, splenomegaly (21.7 cm, compared to 10-12 cm in 
normal adults) (Fig. 1c) and pancytopenia. Fever and cytopenia improved with corticosteroids, 
but lymphopenia, deficiency in immunoglobulin (Ig)M, IgG, IgA and IgE, ongoing colitis, lung 
infiltrates and recurrent upper respiratory tract infections persisted (Fig. 1c and Table 1 and 
Supplementary Table 1). A colonic biopsy demonstrated inflammatory changes with crypt 
branching and prominent lymphocytic infiltrates around the crypts (Fig. 1d), with significantly 
reduced FoxP3+ regulatory T (Treg) cells compared with healthy controls or patients with 
classical IBD (Fig. 1e). The early disease onset and unusual symptoms in the absence of family 
history prompted us to perform whole exome sequencing on the patient and healthy parents as a 
trio. After excluding all variants with minor allele frequency (MAF) >0.01, no candidate variants 
remained to support a hypothesis of recessive inheritance. We found a heterozygous novel de 
novo, non-synonymous mutation in BACH2, c.T71C, predicted to be deleterious (Supplementary 
Table 2), substituting a highly conserved leucine with proline (L24P), and not present in healthy 
family members (Fig. 1b and Supplementary Figure 1). A second family that had been 
previously investigated by exome sequencing (Fig. 1a– Family B) was found to have a 
heterozygous point mutation in BACH2, c.G2362A (Fig. 1b), substituting glutamic acid with 
lysine (E788K) in a father and daughter, both of whom presented with inflammation of both small 
and large bowel, together with pulmonary disease, including recurrent sino-pulmonary infections, 
bronchiectasis and fibrosis (Fig. 1c and Supplementary Table 1). The BACH2 mutation was not 
seen in healthy family members (Supplementary Figure 1). The father (proband) was deficient 
in all Ig sub-types; his daughter had undetectable IgA (Supplementary Table 1). Detailed 
clinical features are described in the Supplementary text, Tables 1 and Supplementary Fig 1. 
We found no low MAF variants nor causative mutations in genes causing monogenic IBD or 
other recognized primary immunodeficiencies29-31. 
 
In the lymphocytes of affected individuals, we found decreased expression of FoxP327 in 
CD4+CD25highCD127low regulatory T cells (Tregs) (Fig. 2a) and increased expression of the Th1 
transcription factor T-bet and two gut-homing receptors, CCR9 and β7-integrin on CD4+ T 
cells32,33 (Fig. 2b). In the patient B cells, we found a marked reduction in CD19+CD27+ memory 
and IgG class-switched CD27+IgG+ B cells (Fig. 2c). These features were not present in healthy 
controls or patients with inflammatory bowel disease (IBD) (Supplementary Fig. 2a). 
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Furthermore, CD24+CD38+ transitional B cells were increased in patients (Supplementary Fig. 
2b). In vitro activation of naïve B cells from patients resulted in significantly impaired 
plasmablast generation, class-switch recombination and class-switched antibody secretion in the 
presence of IL-21 (Figs. 2d and 2e), suggesting a defect in B cell maturation towards memory 
and plasma cells, similar to Bach2 knockout mice34. Polyclonal activation of T cells resulted in 
reduced CD4+ T cell proliferation compared with healthy controls (Supplementary Fig. 2c). In 
summary, the immunopheontype of patients with mutations in BACH2 consisted of compromised 
Tregs, enhanced Th1 differentiation, impaired proliferation and defective B cell maturation and Ig 
class switching. 
 
BACH2 gene mutations result in a reduction in BACH2 protein in patients and cell lines  
We next measured BACH2 protein expression by flow cytometry and found it was reduced in 
patient CD4+, CD8+ and B lymphocytes despite normal mRNA expression (Figs. 3a and 3b). We 
measured protein expression of Flag-tagged vectors encoding wild-type (WT) or mutant forms of 
Bach2 in transfected HEK293T cells and found that mutant forms of the protein accumulated less 
than WT (Fig. 3c), at all time points measured and concentrations of vector used 
(Supplementary Fig. 3a-b). PRDM1, which encodes the protein BLIMP1, is a target of BACH2-
mediated transcriptional repression24. We found that patient naïve B cells and CD4+ T cells 
expressed significantly higher levels of PRDM1 mRNA compared with healthy controls 
suggesting a release from BACH2 repression (Figs. 3d and 3e). Furthermore, this difference 
could be reversed by forced expression of WT BACH2 in patient CD4+ lymphocytes (Fig. 3e). 
These observations suggested a causal relationship between reduced BACH2 levels in patients 
and their cellular phenotype. To confirm this relationship, we silenced BACH2 expression in 
healthy control T and B cells using RNAi by ~50% and carried out functional phenotyping 
(Supplementary Figs. 4a and 4b). Silencing BACH2 in control CD4+ T cells led to a significant 
rise in PRDM1 mRNA (Fig. 3f) and resulted in a reduction in proliferation of CD4+ T cells 
(Supplementary Fig. 4c), in similar fashion to that seen in primary CD4+ T cells of patients 
(Supplementary Fig. 2c). In addition, silencing BACH2 in healthy control B cells, significantly 
suppressed in vitro class switch recombination towards the IgG and IgA isotypes (Fig. 3g). Thus, 
experimental silencing of BACH2 in healthy T and B cells recapitulated the phenotype seen in 
primary cells of the patients. 
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Reduced BACH2 protein expression is caused by the production of abnormal proteins 
Both mutations that we identified affect highly conserved amino acid residues in BACH2 (Fig. 
4a). Murine and human BACH2 share 90% sequence identity and L24 is conserved across 
species and with other members of the BTB/POZ domain family (Supplementary Figs. 5a and 
5b; Supplementary Table 2). L24 resides within α-helix-1 (residues 18-34) of the BTB/POZ 
domain, a key part of the BACH2 homo-dimerization interface (Figs. 4b and 4c). The mutant 
proline residue likely perturbs α-helix-1 of the BTB/POZ domain and places a polar residue into 
the hydrophobic face of that helix, which we predicted would decrease dimer stability 
(Supplementary Table 2). We expressed and purified the BTB domains from both WT and 
L24P mutant proteins. The WT protein was soluble and formed dimers (Fig. 4d), whereas the 
L24P mutant was insoluble in solution, likely misfolded, and formed multiple aggregated species 
(Fig. 4e). E788, the site of the C-terminus mutation, is again highly conserved (Supplementary 
Fig. 5a). Though not characterized by structural studies, it is in proximity to a nuclear export 
signal (Fig. 4a). We found that wild type BACH2 protein was evenly distributed in both 
cytoplasm and nucleus, whereas the E788K mutant protein was aggregated in the cytoplasm with 
relatively little in the nucleus (Fig. 4f and Supplemental Movies 1-2). Similar protein aggregates 
were observed in HEK293T cells transfected with this C-terminal variant (Supplementary Fig. 
5c and Supplemental Movies 3-4). By contrast, aggregates were not detected in lymphocytes 
expressing the L24P mutant from patient A.II.1, although, as noted, L24P mutant BACH2 protein 
expression levels were lower than WT control (Supplementary Fig. 5d). 
 
BACH2 gene mutations do not confer a dominant negative effect 
In both families, the BACH2 gene mutations could potentially act in a dominant negative manner. 
To test this, HEK293T cells were co-transfected with Flag-tagged WT together with untagged 
WT or mutant Bach2 protein-expressing constructs. Neither patient mutant altered WT protein 
expression (Fig. 5a). The experiment was repeated with HEK293T cells co-transfected with 
vectors encoding two tagged WT (HA-Bach2 and Flag-Bach2) forms of the proteins together 
with either untagged WT or mutant Bach2 protein-coding constructs (Fig. 5b). Co-
immunoprecipitation studies showed that WT untagged Bach2, but not mutant forms of the 
protein, interfered with dimerization between HA and Flag-tagged WT Bach2. Furthermore, 
when WT Flag-Bach2 was co-transfected together with HA-tagged WT, L24P or E786K Bach2, 
we detected reduced mutant HA-Bach2 bound to Flag-tagged WT Bach2 after 
immunoprecipitation, in proportion to the reduction in protein accumulation, implying limited, if 
any, effects on WT Bach2 (Supplementary Fig. 6a). All these results were consistent with our 
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earlier findings of loss of stability of the mutant proteins compared with wild type proteins (Fig. 
4). Finally, we used retroviral constructs encoding murine WT or mutant Bach2 genes to 
transduce Prdm1-YFP transgenic CD4+ T cells. Forced expression of wild type Bach2 alone led 
to a significant reduction in the expression of Prdm1-YFP, but co-transduction with either mutant 
form of Bach2 did not interfere with repression of the Prdm1 reporter in primary mouse 
lymphocytes (Fig. 5c). Collectively, these data indicate that neither BACH2 mutation exerted a 
dominant negative effect. 
 
Bach2+/- mice have similar defects in T and B cells 
In the absence of a dominant negative effect we next turned to haploinsufficiency as an 
explanation. Complete absence of BACH2 in mice results in B cell immunodeficiency and fatal 
autoimmunity later in life15,16. If haploinsufficiency is responsible for the defects in lymphocyte 
development observed in our patients, we would expect to see a similar effect in mice 
heterozygous for WT and null alleles (Bach2+/-). We found that Bach2+/- animals manifest 
reduced Bach2 mRNA (Fig. 6a) and protein expression (Fig. 6b) together with elevated Prdm1 
mRNA (Supplementary Fig. 7a). There was no difference in the numbers of CD4+ and CD8+ T 
cells, B cells or plasma cells in unchallenged mice (Supplementary Figs. 7b and 7c) but 
Bach2+/- mice did have a small but significant reduction in Foxp3+ cells together with significant 
increases in CCR9+ and β7-integrin+ cells in CD4+ T cells (Figs. 6c and 6e). We next immunized 
WT and Bach2+/- mice with 4-hydroxy-3-nitrophenylacetyl hapten-conjugated chicken gamma 
globulin (NP-CGG) in alum and analyzed the splenic B cell response. Immunized Bach2+/- mice 
exhibited minimal induction of both IgG1 class switched-B220highCD138- B cells and 
B220lowCD138+ plasma cells compared to WT mice (Fig. 6f). The proportion of germinal center 
B220+Ki67+Bcl6+ B cells was also reduced in Bach2+/- mice (Fig. 6g), supporting a 
haploinsufficiency model.  
 
Genes that are associated with super-enhancer structures are associated with haplo-
insufficiency syndromes. 
Taken together, our data argue that the maintenance of a threshold concentration of BACH2 is 
crucial for proper immunoregulation. Mutations of other TFs have been reported to cause 
haploinsufficient disorders35. BACH2 expression is regulated in a complex manner and the 
BACH2 locus contains an archetypal SE (Fig. 7a)12-14,16,36,37. We therefore hypothesized that SE 
structure may be enriched among genes causing haploinsufficiency (HI) diseases. To this end, we 
compared genetic disorders mediated by HI (372 genes) versus autosomal recessive (AR) 
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inheritance (259 genes) to haplosufficient (HS) genes (those where single allele deletions are 
inconsequential; 901 genes) (Ref. 38 and Methods). To validate these three groups, we evaluated 
the probability of loss of function intolerance (pLI) score (as estimated by ExAc39), where a score 
of 0 predicts that loss of a single copy of the gene is well tolerated whereas a score of 1 predicts 
that loss of a single copy is poorly tolerated and likely to result in a disease. As expected, the 
median pLI score for our HI list was significantly higher than the others (median values of 0.86, 
0.0005 and 0.004 for HI, HS and AR recessive genes, respectively) (Fig. 7b). Moreover, HI genes 
were substantially more likely to have SE architecture, as denoted by especially high acetylated 
histone H3 lysine 27 (H3K27Ac) signal, a hallmark of active enhancers40 (Figs. 7c and 7d, 
Supplementary Fig. 8a and supplementary Table 3). In contrast, there was no difference in the 
frequency of typical enhancers between the three groups (Fig. 7d). We next compared the 
function of genes between the three groups and found that HI genes were more likely to encode 
transcription factors than genes associated with AR inheritance or HS genes (Fig. 7e, 
Supplementary Figs. 8b and 8c). To address any potential confounding abundance of 
transcription factor genes in SE, we also divided our list of HI genes into those that code for 
transcription factors and those that code for all other proteins and compared the frequency of SEs 
(Supplementary Fig. 8c). We found that even after discounting TF genes, haploinsufficiency 
disease-causing genes are heavily enriched for SE architecture compared to HS and AR genes 
(Supplementary Fig. 8d). We next asked whether SE-bearing genes have lesser tolerance to 
loss-of-function mutations and whether the ‘size’ of the SE correlates with this effect. We 
expanded our analysis to a collection of genes regulated by SEs called across more than 100 
tissues (dbSuper database41) and observed both a striking increase in the probability of loss of 
function intolerance score with increasing SE signal size and a concomitant increase in the 
proportion of transcription factor genes (Fig. 7f). Thus, not only the presence of an SE but also its 
“size” correlates with likelihood of disease caused by haploinsufficiency.  
 
SE architecture has been shown previously to associate with human disease loci in genome-wide 
association studies (GWAS)14,36,42. This is the case for BACH216,22, which was consistently in the 
top 1% of human SE genes by H3K27Ac SE signal intensity in naïve CD4+ T, naïve CD8+ T and 
B cells (Supplementary Figs. 8e-g). Based on the SE enrichment among HI genes, we next 
asked whether there would be general enrichment of GWAS “hits” in genes associated with 
haploinsufficient disease. In agreement with this hypothesis, we found that there was highly 
significant enrichment of disease-associated SNVs within this gene set (Fig. 7g and 
Supplementary Table 5). To exclude gene size as a potential confounding factor, the analysis 
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was repeated on subsets of genes of less than 50 kb and again we found more GWAS associations 
in genes associated with HI syndromes compared to HS genes (Supplementary Fig. 8h). Thus, 
HI genes are enriched for both SEs and GWAS “hits”.  
Discussion 
Adaptive immunity is critically dependent on appropriate differentiation and maturation of 
lymphocytes. Several complex steps of differentiation are required to form mature cells that 
occupy specific niches and carry out defined roles within the immune system. Key to the 
regulation of lymphocyte differentiation is precise control over expression of many transcription 
factors (TFs) that form complex regulatory networks. The identification of both mice and humans 
with dramatic early onset stereotypical autoimmune disease associated with a homozygous loss of 
gene expression has led to the identification of many key regulatory TFs, most notably FOXP3, 
the master TF of T regulatory (Treg) cells27.  
 
The reduction in the cost and time it takes to perform whole exome sequencing has allowed 
patients with no family history to be analysed for genetic mutations. Comparing patients’ DNA 
sequence with healthy parents identifies the appearance of de novo mutations that would 
otherwise be missed if a positive family history was required prior to any investigation. Using this 
strategy a number of heterozygous mutations associated with autoimmune diseases have recently 
been discovered. 
 
BACH2 plays a major role in the regulation of the adaptive immune system. Its own expression is 
tightly regulated by the presence of a large super-enhancer region within the Bach2 locus14. The 
role of BACH2 has been elucidated by the investigation of Bach2 deficient mice that have a 
defect in B cell class switch recombination together with a deficiency of Treg differentiation. In 
mice, this combination results in a chronic variable immunodeficiency together with a late onset, 
but progressively fatal, autoimmune syndrome that includes inflammatory enteropathy and 
respiratory infiltrates15. In keeping with its place as an SE associated gene, there is a link between 
single nucleotide polymorphisms within the BACH2 locus and a number of 
autoimmune/inflammatory diseases.  
 
Herein we describe three patients from two families that have heterozygous mutations in BACH2. 
Two of the three presented with a history of early onset autoimmune gastrointestinal disease and 
the third presented later in life. All three have developed a chronic variable immunodeficiency 
characterized by recurrent respiratory tract infections associated with an inability to generate 
appropriate antibody responses to vaccination. Our findings support a role for human BACH2 as 
a key regulator of the human adaptive immune system critical to maintain Treg cell function and 
B cell maturation. Bach2 deficient mice exhibit accelerated T cell senescence26,43 and, in keeping 
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with this, T cells from our patients have a defect in cell proliferation associated with a progressive 
T cell lymphopenia. Many of the autoimmune phenomena in our patient with the L24P mutation 
have been successfully treated with corticosteroids although this has not reduced her chronic 
variable immunodeficiency nor her pneumonitis, which is of some concern as this is a key cause 
of early mortality in Bach2 deficient mice. The father with the E788K mutation has developed 
bronchiectasis later in life. It remains to be seen whether the pneumonitis will be progressive in 
our L24P patient and result in chronic lung damage. 
 
In the first family, the mutant BACH2T71C gene resulted in a protein that is predicted to be unable 
to dimerize and is unstable. In the second family, the mutant BACH2E788K protein again showed 
some evidence of a defect in stability but this was less dramatic, and we saw more evidence of a 
defect in the localisation of the protein with reduced nuclear localisation. We found little 
evidence that either mutant protein acted in a dominant negative manner. Thus we attribute the 
clinical phenotype to BACH2 HI and this conclusion was consistent with our findings and 
previous reports44 that Bach2+/- heterozygote have defects in CSR antibody responses. 
 
Mammalian cells contain tens of thousands of gene enhancer sites that cluster in large numbers 
around a select subset of genes that make up some 5-10% of the total human genome. These 
clusters are collectively known as SEs. GWAS associated mutations tend to associate with these 
gene loci but the significance of this remains unclear. Previous work would suggest that SE genes 
code for proteins whose function is highly dependent on transcription, small changes of which 
would lead to significant changes in cell development. From this we hypothesise that SE genes 
would be susceptible to gene dosage effects in patients with heterozygous mutations. We 
conclude that the relationship between GWAS studies and SE regulated genes occurs not simply 
because these genes transcribe proteins that are important per se but because small changes in the 
expression of SE genes result in large functional changes in the affected cells. 
 
In summary, we describe a new disorder, BACH2-related immunodeficiency and autoimmunity 
(BRIDA) due to heterozygous mutations in BACH2. We found that the mechanism of disease is 
BACH2 HI and that BACH2 is a prototype HI gene exhibiting SE architecture. Given the 
prevalence of heterozygous variants in non-consanguineous human genomes45, it is difficult to 
predict which ones cause disease. We demonstrate that HI diseases are associated with 
heterozygous mutations in SE-regulated genes. As SEs allow complex regulation of gene 
transcription, we conclude that HI genes are carefully regulated due to their SE association and 
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that small changes in their expression level can potentially lead to amplified changes in their 
associated network, especially for TF genes, resulting in significant pathology. Thus, SE-
regulated genes should be more significantly prioritized when interpreting heterozygous variants 
discovered on whole exome/genome sequencing. 
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Methods 
 
Detailed materials and methods are given in the supplementary text. 
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Figure legends 
Figure 1. Pedigrees and phenotype of patients with mutations in BACH2. (a) Pedigrees of 
two families with heterozygous missense coding mutations in BACH2, resulting in L24P (left) 
and E788K (right) amino acid substitutions. Shown are affected heterozygotes (filled symbols) 
and unaffected family members (open symbols). Arrows indicate probands; WT = wild-type 
allele; Mut = mutant allele. (b) Sanger sequencing chromatograms of the affected individuals in 
both families. For each individual, the two alleles of the sequenced region of BACH2 and base 
positions are shown above the chromatograms. Subject A.II.1 had a heterozygous T to C mutation 
at coding position 71 whereas patients B.II.1 and B.III.2 were heterozygous for G to A base 
substitutions at position 2362. (c) Computerized tomography scans showing splenomegaly (arrow 
in upper left) and pulmonary nodules (red circle in upper right) in patient A.II.1 and 
bronchiectasis (dilated airways; arrow in lower left) and fibrosis (“honeycombing” circled in 
lower right) in subject B.II.1. (d) Photomicrograph of a hematoxylin and eosin-stained section 
from a colonic biopsy from patient A.II.1 showing crypt branching and lymphocytic 
inflammatory infiltrate around the crypts. (e) Immunofluorescent staining of colonic biopsy from 
patient A.II.1, control IBD patient and healthy control for nuclear DNA (DAPI, blue), CD3 
(green) and FoxP3(orange). Shown are representative sections (left) and cumulative (mean ± 
sem) quantification (right) from four low power fields per patient (500-3000 CD3+ cells counted 
per low power field); white scale bar = 100 µm in main image and 2 µm in insets. *p<0.05, 
**p<0.01 by t-test. 
Figure 2. Immunophenotype of patients with mutations in BACH2. (a-c) Treg (a), T cell (b) 
and B cell (c) immunophenotype of patient and healthy control peripheral blood cells. Shown are 
total FoxP3 expression (mean fluorescent intensity (MFI)) within CD4+CD25hiCD127lo cells (a), 
expression of the transcription factor T-bet and gut-homing receptors (CCR9 and β7-integrin) in 
bulk CD4+ T cells (b), total memory (c, left) and class-switched memory (c, right) in bulk B 
cells. (d-e) Plasmablast formation (d, left panels), IgG class switch recombination (d, right 
panels) and immunoglobulin secretion (e) in naïve patient and healthy control B cells activated in 
vitro as indicated. Shown are representative flow cytometry plots and cumulative data. N.D. = not 
detected; very low values are shown above the bars for clarity. In (a-d) representative flow 
cytometry plots are shown together with cumulative data (mean ± sem; n = 6 from two 
independent experiments (3 patients and 3 controls measured twice)) from all patients and 
matched controls. Note that IgG secretion in (e) does not include patient B.III.2, who has normal 
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IgG secretion. Bars show mean ± sem throughout. *p<0.05 **p<0.01 ***p<0.001 by t-test (a-c) 
and ANOVA (d and e). 
Figure 3. The cellular phenotype is attributable to reduced BACH2 protein expression. (a) 
BACH2 protein expression in primary immune cells of patients and controls. Shown are 
representative flow cytometry plots with MFIs indicated (left panels) and cumulative BACH2 
protein expression (right panels) from patients relative to controls. (b) Cumulative BACH2 
mRNA expression from naïve B cells of patients and controls. (c) Representative western blot for 
Flag and Hsp70 from lysates of HEK293T cells transfected with empty vector (EV), Flag-tagged 
WT or mutant murine Bach2 (L24P or E786K, the murine equivalent of E788K). Shown are a 
representative blot (left) and cumulative quantifications from n = 5 experiments (right). (d) 
PRDM1 mRNA expression in naïve B cells from patients and healthy controls: cumulative data. 
(e and f) PRDM1 mRNA expression in CD4+ T lymphocytes of healthy controls and patients 
transfected with either control or BACH2 (e) and healthy donor CD4+ T lymphocytes transfected 
with control or BACH2 RNAi (f). (g) Plasmablast formation, IgG class switch recombination and 
IgA secretion in naïve healthy control B cells transfected with control RNAi or RNAi specific for 
BACH2 and activated in vitro as shown (n = 5 independent experiments). Shown are 
representative flow cytometry examples and cumulative data. In (a-g) bars show mean values ± 
sem; patient data are n = 6 from two independent experiments (3 patients and 3 controls measured 
twice); *p<0.05, **p<0.01, ****p<0.0001 by t-test (a, d and f) and ANOVA (c, e and g).  
Figure 4. BACH2L24P haploinsufficiency is caused by failed protein dimerization. (a) 
Schematic of BACH2 protein with indicated domains and sites of point substitutions in patients. 
BTB/POZ, BR-C, ttk and bab or Pox virus and Zinc finger domain; bZIP, basic leucine zipper; 
NES, nuclear export signal. (b), The structure of the Bach2 POZ domain. Ribbon representations 
are based on the crystal structure of the POZ domain, form II (PDB: 3OHV). The structure of the 
wild type protein is shown together with an expanded and rotated view of the interface. The 
intermolecular disulfide formed at position 20 is shown in yellow. The leucine residues at 
position 24 are shown in orange. (c), (top) Interface of the WT POZ domain dimer (PDB: 
3OHV); (bottom) an homology model of the BACH2L24P : WT POZ domain hetero-dimer, 
illustrating local changes. In each model, one monomer has been rendered as a partially 
transparent hydrophobicity surface (Orange = hydrophobic, White = intermediate, Blue = 
hydrophilic). The other monomer is represented as a ribbon (Green). The side chains of selected 
residues at the dimer interface are shown as sticks. Cys20 (Yellow) and Ile23, Leu24, and Leu27 
(all shown in Orange) form a hydrophobic patch on α-helix-1, and two of these patches are in 
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close contact with one another at the WT dimer interface. Please note that the lower diagram is 
not meant to represent the structure accurately but is shown merely to indicate regional changes. 
(d-e) Analytical ultracentrifugation carried out on purified wild type (WT) p.BACH2 (d) and 
mutant p.BACH2L24P (e) BTB/POZ domain. The direction of sedimentation is left to right and M 
indicates the sample meniscus. The WT protein is dimeric (35 kDa) as determined by 
sedimentation equilibrium measurements (shown in d, right) and migrates with a single boundary 
with a sedimentation coefficient (S) of 2.6. The mutant exhibits several boundaries with S values 
ranging from 4 to 18, indicating heterogeneous large protein aggregates (e). (f) Confocal 
microscopy images of primary lymphocytes from healthy control and patient B.II.1 stained for 
BACH2 (green) and Hoechst (blue). Insets show enlarged images of BACH2 staining; 
cytoplasmic aggregates in the patient are highlighted (white arrows). Scale bars: 5 µm in main 
image and 2 µm in inset. Images are representative from 3 independent experiments. Bar graphs 
quantify the number of cells containing aggregates per high power field (HPF) and nuclear 
localization of BACH2. *p<0.05 by t-test.  
Figure 5. Mutant forms of Bach2 do not exert dominant negative effects. (a) Western blot for 
Flag and Hsp70 in HEK293T cells co-transfected at 1:1 ratio with Flag-tagged WT murine Bach2 
and untagged WT and mutant forms of murine Bach2. Shown is a representative from n = 3 
independent experiments. (b) co-immunoprecipitation of Flag- and HA-tagged WT Bach2 
transfected into HEK293T cells together with untagged WT and mutant forms of murine Bach2 at 
1:1:1 vector ratio. Shown is a representative example from n = 3 independent experiments (left) 
and quantification of the co-immunoprecipitated Flag and HA signals (right). (c) Blimp1-YFP 
signal in Blimp1-YFP Tg mouse CD4+ T cells co-transduced at 1:1 ratio with retrovirus 
supernatants encoding WT and mutant forms of murine Bach2. Shown is a representative 
example (left) and cumulative data (mean ± sem) from n = 4 independent experiments (right). 
****p<0.0001 by ANOVA. 
Figure 6. Bach2 haploinsufficient mice have abnormal B cell differentiation and Treg 
numbers. (a) Expression of Bach2 mRNA in B cells of Bach2+/+ and Bach2+/- mice (n=3 per 
genotype). (b) Bach2 protein expression in splenic naïve B cells of Bach2+/+ and Bach2+/- mice. 
Shown is a representative example (left) and cumulative quantification (mean ± sem) (right) from 
n=3 independent experiments. (c-e) Flow cytometry analysis of CD4+ splenocytes in Bach2+/+ and 
Bach2+/- mice. Percentage Foxp3+ (c), CCR9+ (d) and β7-integrin+ (e) are shown with 
representative flow cytometry plots together with histograms (mean ± sem) generated by 
measuring a minimum of six mice per group. (f) IgM and IgG1 staining of B cells (upper panels) 
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and plasma cells (lower panels) in splenocytes of Bach2+/+ and Bach2+/- mice 8 days following 
immunization with 4-Hydroxy-3-nitrophenylacetyl hapten-conjugated chicken gamma globulin 
(NP-CGG) in alum. Representative flow cytometry plots together with histograms (mean ± sem) 
generated by measuring seven mice per group. (g) B220+Ki67+Bcl6+ germinal center B cells in 
splenocytes of Bach2+/+ and Bach2+/- mice 8 days after immunization with NP-CGG in alum. 
Representative flow cytometry plots together with histograms (mean ± sem) generated by 
measuring seven mice per group. All data are representative of 2 independent experiments. 
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA (f) and Mann-Whitney U-test (all other 
panels). 
Figure 7. Coding mutations in genes regulated by super-enhancer (SE) structures cause 
haploinsufficient diseases in humans. (a) The BACH2 locus has SE structures in multiple 
human immune cell types demarcated by H3K27Ac loading. Red fill denotes the presence of an 
SE in the BACH2 locus in a tissue. Source data are indicated. (b) Violin plots showing probability 
of loss of function intolerance scores in haplosufficient (HS), autosomal recessive (AR) and 
haploinsufficient (HI) gene sets. The white circles show median values. Source data: ExAc 
database39. (c) Number of HS, AR or HI genes with and without associated SE architecture in 
humans (see also supplementary Fig. 8a and supplementary Table 3). (d) Pie charts indicating 
the frequency of SE (upper panels) and typical enhancer (TE; lower panels) structures in HS 
(left), HI (middle) and AR (right) genes. (e) Gene ontology (GO) functional annotation 
enrichment in HI genes. Shown are enrichment scores (blue bars) and Benjamini p-values (in 
orange) for the top 5 most significantly enriched terms. (f) Median probability of loss of function 
intolerance (black line) against SE signal size; the percentage of genes that are transcription 
factors (TF, red line) against SE signal size is shown in the inset. For reference, the red line 
asymptotes to the expected level (mean percentage of genes in the human genome that are TFs is 
7.5%). Source data:  ExAc39 and dbSuper41 databases. (g) Pie charts indicating the percentage of 
HS or HI genes that have GWAS disease associations. p-values in d and g are Fisher exact tests; 
NS = non-significant; GWAS = genome-wide association study. 
Table 1. Summary clinical characteristics of patients with missense mutations in BACH2. 
IvIg, intravenous immunoglobulin; EBV, Epstein-Barr virus; RhF, rheumatoid factor, dsDNA, 
double-stranded DNA; ANCA, anti-neutrophil cytoplasmic antibody; p-ANCA, perinuclear 
ANCA; ANA, antinuclear antibody; UC, ulcerative colitis; N/A not assessed. † Absolute values 
given in Supplementary Table 1; * progressive decline in IgG; ‡ positive by immunofluorescence 
but negative for myeloperoxidase and proteinase III antibodies by ELISA. 
 
 Patients 
Demographic and clinical 
characteristics 
A.II.1  B.II.1 B.III.2 
     
Age, Sex 19, F  63, M 40,F 
Lymphadenopathy Yes  Yes Yes 
Splenomegaly Yes  No No 
Intestinal manifestations Yes  Yes Yes 
Chronic diarrhea Yes  Yes Yes 
IBD Colitis  Not 
biopsied 
UC aged 10; 
Crohn’s aged 
32 
Pulmonary manifestations Yes  Yes Yes 
Recurrent sino-pulmonary infections Yes  Yes Yes 
Radiographic changes on chest CT Yes  Yes Not imaged 
Immunoglobulins†     
IgM Low  Low High 
IgG Low  Low High* 
IgA Low  Low Low 
IgE Low  Low Normal 
On IvIg treatment Yes  Yes No 
EBV antibodies N/A (DNA 
negative) 
 N/A High 
RhF N/A  N/A N/A 
dsDNA antibodies Negative  N/A N/A 
ANCA Positive 
(pANCA)‡ 
 N/A N/A 
ANA Negative  N/A Negative 
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